Irinotesin

Irinotecan, the active ingredient in Irinotesin, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer, primarily in adult patients whose disease has progressed after standard therapies. The drug is administered under the supervision of oncology specialists and requires careful monitoring of blood counts and organ function.

GNH USA supplies Irinotesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer.

Metastatic colorectal cancer: improves survival in patients with advanced disease. Adjuvant colon cancer: reduces risk of recurrence after surgical resection. Colorectal cancer combination therapy: used with fluorouracil and leucovorin to enhance treatment efficacy.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: may be managed with antiemetics. - Fatigue: commonly reported during treatment cycles. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss may occur during therapy. - Anemia: decreased red blood cell levels causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: intense inflammation of the colon that can be life‑threatening. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis. - Cardiotoxicity: rare cardiac events such as arrhythmias. - Secondary malignancies: very rare risk of developing new cancers.

Before initiating Irinotecan therapy, clinicians should assess patient suitability and monitor for potential complications.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: check hepatic enzymes prior to each cycle. Maintain hydration: ensure adequate fluid intake to reduce risk of severe diarrhea. Avoid strong CYP3A4 inhibitors: drugs like ketoconazole can increase toxicity. Pregnancy and lactation: use only if potential benefit justifies potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase SN‑38 exposure. - Concurrent myelosuppressive agents: can exacerbate neutropenia and anemia. - High‑dose warfarin: may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug effectiveness. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - Anticoagulants (e.g., heparin): monitor coagulation parameters.